stockrow
Monday 9 November 2026
Export RNAC’s income statement to Excel — free account
Cartesian Therapeutics, Inc.
RNACCartesian Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.8 million, down 92.8% from fiscal 2024.
- Revenue
- −92.9%
- EPS
- −7.84%
- Free cash flow
- −6.15%
Quarter to June 2026, against a year earlier
7.53
0.75
+11.06%
Follow RNAC
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | — |
P/S ratio |
243.58 | 66.95 | 93.05 | — | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — | |
P/Operating CF |
(17.04) | (10.57) | (7.46) | — | |
P/B ratio |
0.00 | 0.00 | 0.00 | — | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | — | |
EV/Sales |
134.18 | 30.80 | 39.74 | — | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | — | |
EV/Operating CF |
(2.32) | (1.17) | (0.97) | — | |
EV/FCF |
(2.14) | (1.09) | (0.91) | — | |
Quick Ratio |
10.44 | 8.45 | 7.46 | 7.19 | |
Current Ratio |
10.67 | 8.65 | 7.65 | 7.48 | |
Net Debt/EBITDA |
7.01 | 1.60 | 4.58 | 3.34 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 16.59% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | (0.42) | |
Asset Turnover |
0.00 | 0.01 | 0.01 | 0.00 | |
Operating CF/Net income |
0.43 | 0.20 | 0.56 | (1.54) | |
Capex/Depreciation |
(2.13) | (0.81) | (0.04) | (0.35) | |
Interest Coverage |
— | — | — | (34.22) | |
Research and Development Expense of Revenue |
3,053.54% | 1,551.11% | 24,952.56% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
1,707.08% | 865.58% | 9,120.51% | 0.00% | |
Intangible Assets out of Total Assets |
0.13 | 0.16 | 0.17 | 0.15 | |
Share Based Compensation of Revenue |
573.01% | 226.40% | 3,106.41% | 0.00% | |
Graham Net Nets |
(0.98) | (1.57) | (1.90) | — | |
Graham Number |
7.78 | 23.64 | 27.04 | — | |
Earnings Yield |
(19.10%) | (70.87%) | (95.77%) | — | |
Free Cash Flow Yield |
(25.79%) | (42.40%) | (46.85%) | — | |
Revenue per Share |
0.02 | 0.04 | 0.00 | 0.00 | |
Operating CF per Share |
(0.60) | (0.68) | (0.82) | (0.72) | |
Capex per Share |
(0.05) | (0.02) | 0.00 | (0.01) | |
Free Cash Flow per Share |
(0.65) | (0.70) | (0.83) | (0.72) | |
Cash per Share |
5.51 | 4.82 | 4.42 | 5.01 | |
Shareholders Equity per Share |
(1.38) | (4.86) | (5.52) | (4.25) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(1.38) | (4.86) | (5.52) | (4.25) | |
Free Cash Flow |
(16.89) | (18.20) | (22.16) | (21.35) | |
Working Capital |
133.46 | 114.34 | 106.09 | 133.07 | |
Capital Expenditures |
(1.29) | (0.49) | (0.03) | (0.27) | |
Net Current Asset Value |
(261.26) | (293.37) | (314.47) | (290.24) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | — | |
Capex to Sales |
2.86 | 0.52 | 0.35 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — | |
| Other line items | |||||
Average Receivables |
3.27 | 0.99 | 1.01 | 0.28 | |
Average Payables |
1.37 | 0.79 | 1.85 | 0.75 | |
Average Assets |
414.00 | 365.72 | 348.76 | 353.76 | |
Average Common Equity |
(17.55) | (66.52) | (84.95) | (63.88) |
Columns are period end dates · fundamentals updated 26 Oct 2026